{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:55:20Z","timestamp":1769262920692,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It is essential to monitor the occurrence of drug-resistant strains and to provide guidance for clinically adapted antiviral treatment of HIV\/AIDS. In this study, an individual patient\u2019s HIV-1 pol gene encoding the full length of protease and part of the reverse transcriptase was packaged into a modified lentivirus carrying dual-reporters ZsGreen and luciferase. The optimal coefficient of correlation between drug concentration and luciferase activity was optimized. A clear-cut dose-dependent relationship between lentivirus production and luciferase activity was found in the phenotypic testing system. Fold changes (FC) to a wild-type control HIV-1 strain ratios were determined reflecting the phenotypic susceptibility of treatment-exposed patient\u2019s HIV-1 strains to 12 HIV-1 inhibitors including 6 nucleoside reverse-transcriptase inhibitors (NRTIs), 4 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 2 protease inhibitors (PIs). Phenotypic susceptibility calls from 8 HIV-1 infected patients were consistent with 80\u201390% genotypic evaluations, while phenotypic assessments rectified 10\u201320% genotypic resistance calls. By a half of replacement with ZsGreen reporter, the consumption of high cost Bright-Glo Luciferase Assay is reduced, making this assay cheaper when a large number of HIV-1 infected individuals are tested. The study provides a useful tool for interpreting meaningful genotypic mutations and guiding tailored antiviral treatment of HIV\/AIDS in clinical practice.<\/jats:p>","DOI":"10.1038\/srep33559","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T09:35:55Z","timestamp":1474277755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A simple and cost-saving phenotypic drug susceptibility testing of HIV-1"],"prefix":"10.1038","volume":"6","author":[{"given":"Yunceng","family":"Weng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peifang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Allain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,19]]},"reference":[{"key":"BFsrep33559_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1592\/phco.26.8.1111","volume":"26","author":"FJ Piacenti","year":"2006","unstructured":"Piacenti, F. J. An Update and Review of Antiretroviral Therapy. Pharmacotherapy. 26, 1111\u20131133 (2006).","journal-title":"Pharmacotherapy"},{"key":"BFsrep33559_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/COH.0b013e32833a6c32","volume":"5","author":"R Granich","year":"2010","unstructured":"Granich, R. et al. Highly Active Antiretroviral Treatment as Prevention of HIV Transmission: Review of Scientific Evidence and Update. Curr Opin HIV AIDS. 5, 298\u2013304 (2010).","journal-title":"Curr Opin HIV AIDS"},{"key":"BFsrep33559_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jac\/dkm499","volume":"61","author":"RW Burgoyne","year":"2008","unstructured":"Burgoyne, R. W. & Tan, D. H. Prolongation and Quality of Life for HIV-infected Adults Treated with Highly Active Antiretroviral Therapy (HAART): A Balancing Act. J Antimicrob Chemother. 61, 469\u2013473 (2008).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep33559_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev.immunol.18.1.665","volume":"18","author":"T Pierson","year":"2000","unstructured":"Pierson, T., McArthur, J. & Siliciano, R. F. Reservoirs for HIV-1: Mechanisms for Viral Persistence in the Presence of Antiviral Immune Responses and Antiretroviral Therapy. Annu Rev Immunol. 18, 665\u2013708 (2000).","journal-title":"Annu Rev Immunol"},{"key":"BFsrep33559_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S1386-6532(00)00163-3","volume":"21","author":"JG Garcia-Lerma","year":"2001","unstructured":"Garcia-Lerma, J. G. & Heneine, W. Resistance of Human Immunodeficiency Virus Type 1 to Reverse Transcriptase and Protease Inhibitors: Genotypic and Phenotypic Testing. J Clin Virol. 21, 197\u2013212 (2001).","journal-title":"J Clin Virol."},{"key":"BFsrep33559_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jac\/dkt316","volume":"69","author":"GL Melikian","year":"2014","unstructured":"Melikian, G. L. et al. Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Cross-Resistance: Implications for Preclinical Evaluation of Novel NNRTIs and Clinical Genotypic Resistance Testing. J Antimicrob Chemother. 69, 12\u201320 (2014).","journal-title":"J Antimicrob Chemother"},{"key":"BFsrep33559_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.antiviral.2006.05.003","volume":"71","author":"J Vercauteren","year":"2006","unstructured":"Vercauteren, J. & Vandamme, A. M. Algorithms for the Interpretation of HIV-1 Genotypic Drug Resistance Information. Antiviral Res. 71, 335\u2013342 (2006).","journal-title":"Antiviral Res"},{"key":"BFsrep33559_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jac\/dkg016","volume":"51","author":"S Paolucci","year":"2003","unstructured":"Paolucci, S. et al. Comparison of Levels of HIV-1 Resistance to Protease Inhibitors by Recombinant Versus Conventional Virus Phenotypic Assay and Two Genotypic Interpretation Procedures in Treatment-Naive and HAART-experienced HIV-infected Patients. J Antimicrob Chemother. 51, 135\u2013139 (2003).","journal-title":"J Antimicrob Chemother."},{"key":"BFsrep33559_CR9","first-page":"223","volume":"11","author":"RD MacArthur","year":"2009","unstructured":"MacArthur, R. D. Understanding HIV Phenotypic Resistance Testing: Usefulness in Managing Treatment-Experienced Patients. AIDS Rev. 11, 223\u2013230 (2009).","journal-title":"AIDS Rev."},{"key":"BFsrep33559_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1128\/AAC.37.5.1095","volume":"37","author":"AJ Japour","year":"1993","unstructured":"Japour, A. J. et al. Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother. 37, 1095\u20131101 (1993).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep33559_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","volume":"44","author":"CJ Petropoulos","year":"2000","unstructured":"Petropoulos, C. J. et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1. Antimicrob Agents Chemother. 44, 920\u2013928 (2000).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep33559_CR12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00705-015-2386-2","volume":"160","author":"S Wu","year":"2015","unstructured":"Wu, S., Yan, P., Yan, Y., Qiu, L. & Xie, M. A Single-Loop Recombinant Pseudotyped-Virus-Based Assay to Detect HIV-1 Phenotypic Resistance. Arch Virol. 160, 1385\u20131395 (2015).","journal-title":"Arch Virol"},{"key":"BFsrep33559_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF03256421","volume":"15","author":"Z Jia","year":"2011","unstructured":"Jia, Z. et al. Phenotypic Analysis of HIV-1 Genotypic Drug-Resistant Isolates From China, Using a Single-Cycle System. Mol Diagn Ther. 15, 293\u2013301 (2011).","journal-title":"Mol Diagn Ther"},{"key":"BFsrep33559_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jac\/42.2.269","volume":"42","author":"K Hertogs","year":"1998","unstructured":"Hertogs, K. et al. A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs. Antimicrob Agents Chemother. 42, 269\u2013276 (1998).","journal-title":"Antimicrob Agents Chemother."},{"key":"BFsrep33559_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijid.2015.06.011","volume":"37","author":"S Chang","year":"2015","unstructured":"Chang, S. et al. Comparison of Susceptibility of HIV-1 Variants to Antiretroviral Drugs by Genotypic and Recombinant Virus Phenotypic Analyses. Int J Infect Dis. 37, 86\u201392 (2015).","journal-title":"Int J Infect Dis"},{"key":"BFsrep33559_CR16","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"R Zufferey","year":"1998","unstructured":"Zufferey, R. et al. Self-Inactivating Lentivirus Vector for Safe and Efficient in vivo Gene Delivery. J Virol. 72, 9873\u20139880 (1998).","journal-title":"J Virol."},{"key":"BFsrep33559_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ol.2013.1652","volume":"7","author":"D Upreti","year":"2014","unstructured":"Upreti, D., Pathak, A. & Kung, S. K. Lentiviral Vector-Based Therapy in Head and Neck Cancer(Review). Oncol Lett. 7, 3\u20139 (2014).","journal-title":"Oncol Lett."},{"key":"BFsrep33559_CR18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/135965350801300212","volume":"13","author":"DJ McColl","year":"2008","unstructured":"McColl, D. J., Chappey, C., Parkin, N. T. & Miller, M. D. Prevalence, Genotypic Associations and Phenotypic Characterization of K65R, L74V and Other HIV-1 RT Resistance Mutations in a Commercial Database. Antivir Ther. 13, 189\u2013197 (2008).","journal-title":"Antivir Ther."},{"key":"BFsrep33559_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1677\/erc.1.00776","volume":"11","author":"A Ring","year":"2004","unstructured":"Ring, A. & Dowsett, M. Mechanisms of Tamoxifen Resistance. Endocr Relat Cancer. 11, 643\u2013658 (2004).","journal-title":"Endocr Relat Cancer"},{"key":"BFsrep33559_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/COH.0b013e328331c14f","volume":"4","author":"PM Grant","year":"2009","unstructured":"Grant, P. M. & Zolopa, A. R. The Use of Resistance Testing in the Management of HIV-1-infected Patients. Curr Opin HIV AIDS. 4, 474\u2013480 (2009).","journal-title":"Curr Opin HIV AIDS"},{"key":"BFsrep33559_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang, M. W. & Shafer, R. W. HIV-1 Antiretroviral Resistance: Scientific Principles and Clinical Applications. Drugs. 72, e1\u2013e25 (2012).","journal-title":"Drugs"},{"key":"BFsrep33559_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1479-5876-9-14","volume":"9","author":"J Fehr","year":"2011","unstructured":"Fehr, J. et al. Replicative Phenotyping Adds Value to Genotypic Resistance Testing in Heavily Pre-Treated HIV-infected Individuals\u2013The Swiss HIV Cohort Study. J Transl Med. 9, 14 (2011).","journal-title":"J Transl Med"},{"key":"BFsrep33559_CR23","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1097\/INF.0b013e31829f09cf","volume":"32","author":"W Dehority","year":"2013","unstructured":"Dehority, W., Deville, J. G., Zilbermann, J. L. & Viani, R. M. HIV-1 Phenotypic Drug Resistance Testing Among Highly Treatment Experienced and Poorly Adherent Youth. Pediatr Infect Dis J. 32, 1158 (2013).","journal-title":"Pediatr Infect Dis J"},{"key":"BFsrep33559_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/01.qai.0000147526.64863.53","volume":"38","author":"J Zhang","year":"2005","unstructured":"Zhang, J., Rhee, S. Y., Taylor, J. & Shafer, R. W. Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays. J Acquir Immune Defic Syndr. 38, 439\u2013444 (2005).","journal-title":"J Acquir Immune Defic Syndr"},{"key":"BFsrep33559_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000332013","volume":"55","author":"T Pattery","year":"2012","unstructured":"Pattery, T. et al. Development and Performance of Conventional HIV-1 Phenotyping (Antivirogram(R)) and Genotype-Based Calculated Phenotyping Assay (virco(R)TYPE HIV-1) On Protease and Reverse Transcriptase Genes to Evaluate Drug Resistance. Intervirology. 55, 138\u2013146 (2012).","journal-title":"Intervirology"},{"key":"BFsrep33559_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jcv.2009.10.001","volume":"47","author":"S Napravnik","year":"2010","unstructured":"Napravnik, S., Cachafeiro, A., Stewart, P., Eron, J. J. & Fiscus, S. A. HIV-1 Viral Load and Phenotypic Antiretroviral Drug Resistance Assays Based On Reverse Transcriptase Activity in Comparison to Amplification Based HIV-1 RNA and Genotypic Assays. J Clin Virol. 47, 18\u201322 (2010).","journal-title":"J Clin Virol."},{"key":"BFsrep33559_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/jmv.23507","volume":"85","author":"E Agneskog","year":"2013","unstructured":"Agneskog, E., Nowak, P., Kallander, C. F. & Sonnerborg, A. Evaluation of Etravirine Resistance in Clinical Samples by a Simple Phenotypic Test. J Med Virol. 85, 703\u2013708 (2013).","journal-title":"J Med Virol"},{"key":"BFsrep33559_CR28","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1128\/JCM.01636-12","volume":"50","author":"MC Puertas","year":"2012","unstructured":"Puertas, M. C. et al. Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates. J Clin Microbiol. 50, 3909\u20133916 (2012).","journal-title":"J Clin Microbiol"},{"key":"BFsrep33559_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/nar\/gkg100","volume":"31","author":"SY Rhee","year":"2003","unstructured":"Rhee, S. Y. et al. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Nucleic Acids Res. 31, 298\u2013303 (2003).","journal-title":"Nucleic Acids Res."},{"key":"BFsrep33559_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1097\/00002030-200108170-00003","volume":"15","author":"AL Dunne","year":"2001","unstructured":"Dunne, A. L. et al. Comparison of Genotyping and Phenotyping Methods for Determining Susceptibility of HIV-1 to Antiretroviral Drugs. AIDS. 15, 1471\u20131475 (2001).","journal-title":"AIDS"},{"key":"BFsrep33559_CR31","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/jobm.201300415","volume":"54","author":"J Yang","year":"2014","unstructured":"Yang, J., Geng, W., Zhang, M., Han, X. & Shang, H. Discordance Between Genotypic Resistance and Pseudovirus Phenotypic Resistance in AIDS Patients After Long-Term Antiretroviral Therapy and Virological Failure. J Basic Microbiol. 54, 1120\u20131125 (2014).","journal-title":"J Basic Microbiol."},{"key":"BFsrep33559_CR32","doi-asserted-by":"publisher","first-page":"e34708","DOI":"10.1371\/journal.pone.0034708","volume":"7","author":"M Bronze","year":"2012","unstructured":"Bronze, M. et al. HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation is Not Dependent On the Subtype of the Virus Backbone. PLoS One. 7, e34708 (2012).","journal-title":"PLoS One"},{"key":"BFsrep33559_CR33","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1086\/503914","volume":"42","author":"TF Liu","year":"2006","unstructured":"Liu, T. F. & Shafer, R. W. Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. Clin Infect Dis. 42, 1608\u20131618 (2006).","journal-title":"Clin Infect Dis"},{"key":"BFsrep33559_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jmb.2006.09.073","volume":"365","author":"CE Cases-Gonz\u00e1lez","year":"2007","unstructured":"Cases-Gonz\u00e1lez, C. E., Franco, S., Mart\u00ednez, M. A. & Men\u00e9ndez-Arias, L. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine. J Mol Biol 365, 298\u2013309 (2007).","journal-title":"J Mol Biol"},{"key":"BFsrep33559_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1089\/aid.2011.0128","volume":"28","author":"AA da Silveira","year":"2012","unstructured":"da Silveira, A. A., Cardoso, L. P., Francisco, R. B. & de Ara\u00fajo Stefani, M. M. HIV type 1 molecular epidemiology in pol and gp41 genes among naive patients from Mato Grosso do Sul State, central western Brazil. AIDS Res Hum Retroviruses 28, 304\u2013307 (2012).","journal-title":"AIDS Res Hum Retroviruses"},{"key":"BFsrep33559_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1086\/319231","volume":"32","author":"GJ Hanna","year":"2001","unstructured":"Hanna, G. J. & D\u2019Aquila, R. T. Clinical Use of Genotypic and Phenotypic Drug Resistance Testing to Monitor Antiretroviral Chemotherapy. Clin Infect Dis. 32, 774\u2013782 (2001).","journal-title":"Clin Infect Dis"},{"key":"BFsrep33559_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"L Naldini","year":"1996","unstructured":"Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272, 263\u2013267 (1996).","journal-title":"Science"},{"key":"BFsrep33559_CR38","doi-asserted-by":"publisher","first-page":"e42455","DOI":"10.1371\/journal.pone.0042455","volume":"7","author":"L Zhang","year":"2012","unstructured":"Zhang, L. et al. Recombinant Interferon-Gamma Lentivirus Co-Infection Inhibits Adenovirus Replication Ex Vivo. PLoS One. 7, e42455 (2012).","journal-title":"PLoS One"},{"key":"BFsrep33559_CR39","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.gene.2012.01.071","volume":"498","author":"SC Ngai","year":"2012","unstructured":"Ngai, S. C., Rosli, R., Nordin, N., Veerakumarasivam, A. & Abdullah, S. Lentivirus Vector Driven by Polybiquitin C Promoter without Woodchuck Posttranscriptional Regulatory Element and Central Polypurine Tract Generates Low Level and Short-Lived Reporter Gene Expression. Gene. 498, 231\u2013236 (2012).","journal-title":"Gene"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep33559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33559","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:33:47Z","timestamp":1672900427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep33559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep33559"],"URL":"https:\/\/doi.org\/10.1038\/srep33559","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,19]]},"assertion":[{"value":"26 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33559"}}